Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after lung transplantation, for which several risk factors including pretransplant seronegativity for Epstein-Barr virus are known. However, the impact of cytomegalovirus on PTLD remains to be determined. Here, we describe a case of Epstein-Barr virus-associated polymorphic PTLD that developed shortly after treatment for cytomegalovirus reactivation in a lung transplant recipient who was preoperatively seropositive for both cytomegalovirus and Epstein-Barr virus.
MeSH terms
-
Antiviral Agents / administration & dosage
-
Biopsy
-
Cytomegalovirus / pathogenicity*
-
Cytomegalovirus Infections / diagnosis
-
Cytomegalovirus Infections / drug therapy
-
Cytomegalovirus Infections / virology*
-
Epstein-Barr Virus Infections / diagnosis
-
Epstein-Barr Virus Infections / drug therapy
-
Epstein-Barr Virus Infections / virology*
-
Ganciclovir / administration & dosage
-
Herpesvirus 4, Human / pathogenicity*
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Lung Transplantation / adverse effects*
-
Lymphoproliferative Disorders / diagnosis
-
Lymphoproliferative Disorders / drug therapy
-
Lymphoproliferative Disorders / virology*
-
Male
-
Middle Aged
-
Tomography, Emission-Computed, Single-Photon
-
Treatment Outcome
-
Vidarabine / administration & dosage
-
Virus Activation*
Substances
-
Antiviral Agents
-
Immunosuppressive Agents
-
Vidarabine
-
Ganciclovir